C ervical total disc replacement has been studied as a motion-preserving alternative to anterior cervical discectomy and fusion (ACDF). Several high-level clinical trials have been performed and their 2-year results presented with notable consistency. [1] [2] [3] [4] [5] Longer-term outcomes are now becoming more widely available. [6] [7] [8] [9] [10] [11] [12] [13] The 2-year results of a US Food and Drug Administration investigational device exemption (IDE) prospective, randomized clinical trial on a nonconstrained disc replacement device, the PCM Cervical Disc (NuVasive Inc., San Diego, CA), versus ACDF have been reported. 5 The results of the same trial with complete follow-up out to 5 years and ongoing followup up to 7 years are reported herein.
MATERIALS AND METHODS

Study Design
A prospective, multicenter, randomized, institutional review board-approved clinical trial was conducted under a Food and Drug Administration-approved IDE to compare the safety and effectiveness of the PCM Cervical Disc with ACDF with allograft and plate in treating patients with a degenerated cervical disc at 1 level from C3-C4 to C7-T1. The details of the PCM device, surgical techniques of both treatment groups, and the trial design were described in the publication of the 2-year results. 5 A total of 416 patients were randomized (224 PCM, 192 ACDF) at 24 investigational sites within the United States. Of the randomized patients, 218 PCM and 185 ACDF patients underwent surgical treatment between January 2005 and December 2007, including 49 (29 PCM, 20 ACDF), approximately 12%, with prior adjacent or nonadjacent single-level fusions. Patients were evaluated preoperatively, intraoperatively, immediately postoperatively, and then at 1.5, 3, 6, and 12 months, and annually thereafter. Of the treated patients, 163 PCM and 130 ACDF patients were considered per protocol at 5 years postoperative. Observable data were available through 7 years postoperative on 68 PCM and 42 ACDF patients, among whom safety measures such as adverse events and rates of secondary surgery are reported. A fl ow diagram of patient accountability is presented in Figure 1 .
Fisher exact test was used to compare categorical variables and success rates between the PCM and ACDF groups. To compare continuous variables, either the t test or the Mann-Whitney-Wilcoxon test was used. To assess statistically signifi cant improvement within each treatment group from preoperative to the latest visit, a paired t test was used. 
Clinical and Radiographical Outcome Assessments
Evaluations included patient-reported self-assessments, physical and neurological examination, and quantitative and qualitative radiographical analysis. Validated self-assessment outcomes measures included neck disability index (NDI) (a measure of pain-related dysfunction), 14 , 15 36-Item Short Form Health Survey (SF-36) mental and physical general health surveys (mental component summary and physical component summary), 16 and neck and arm pain scores on a 0-to 100-mm visual analogue scale (VAS). Success on NDI, neck and worst arm pain, and SF-36 scores was defi ned as a minimum 20%, 20-mm, and 15% improvement over the preoperative score, respectively. Neurological examinations evaluated muscle strength, sensory defi cit, and refl ex functions. Neurological success was defi ned as the postoperative maintenance or improvement in each of the individual neurological evaluations compared with the preoperative status. Additional clinical assessments included dysphagia (0-to 100-mm VAS) and patient satisfaction (0-to 100-mm VAS and questionnaire). All adverse event occurrences were recorded prospectively, categorized, and evaluated for causality. Treatment group trends were also assessed.
Plain radiographs were obtained and consisted of neutral lateral and anteroposterior, fl exion/extension, and lateral bending fi lms. Preoperative computed tomographic scans and magnetic resonance images were also collected. All radiographical analyses were performed by an independent radiographical review service (Medical Metrics Inc., Houston, TX). Fusion was defi ned as evidence of continuous bridging bone between the adjacent endplates of the involved motion segment, radiolucent lines at 50% of the graft-vertebra interfaces or less, and 2 ° or less segmental rotation on lateral fl exion/ extension radiographs. Disc heights were measured at each time point, and normal disc height defi ned as 80% or more that of the disc superiorly adjacent to the index operative level. Success in maintenance of disc height over time was defi ned as measuring 80% or more of the postoperative height. Heterotopic ossifi cation was classifi ed as grade 0 (none) through grade IV (ankylosed). 17 Signs of adjacent-level degeneration were independently graded on the basis of observation of disc height loss (compared with adjacent normal discs), presence and size of osteophytes, and endplate sclerosis (thickening and density compared with adjacent normal discs). Each observation was scored and a total score summed to within a range of 0 to 9. 18 Total score was further categorized on a 4-point scale of degeneration: 0 (none: total score of 0), 1 (mild: total score of 1-3), 2 (moderate: total score of 4-6), and 3 (severe: total score of 7-9). Rates of success on this measure were reported and required no worsening of the score compared with preoperative baseline. 
RESULTS
Baseline patient demographics and treatment characteristics have been previously reported, showing no differences between groups. 5 At 5 years, the overall follow-up rate, based on the modifi ed intent-to-treat population, was 74.8% (163/218) in the PCM group and 70.3% (130/185) in the ACDF group. Observable data were available through patients having reached 7 years postoperatively on 31.2% (68/218) PCM and 22.7% (42/185) ACDF patients, among whom safety measures such as adverse events and rates of secondary surgery are reported.
Neck Disability Index
Mean NDI improved signifi cantly over preoperative scores at all postoperative time points in both treatment groups ( P < 0.001). The mean improvement in NDI was greater in the PCM group at all postoperative time points than in the ACDF group ( Figure 2 ), the difference increasing over time. Mean NDI score at 5 years was signifi cantly lower in the PCM group (20.4 vs . 28.5; P = 0.001). At 5 years, NDI success, defi ned as 20% improvement or more compared with preoperative score, was achieved by 85.0% in the PCM group compared with 74.2% in the ACDF group ( P = 0.026) ( Table 1 and Figure 3 ).
Neck and Worst Arm Pain
Mean VAS pain scores improved signifi cantly over preoperative scores for all postoperative time points ( P < 0.001) in both treatment groups ( Figure 4A,B ) . The mean neck pain VAS score was lower in the PCM group at all postoperative time points than that in the ACDF group, signifi cantly so at 5 years ( P = 0.002). Mean VAS scores for worst arm pain were not statistically different between groups at any time point ( P > 0.05) ( Figure 4B ). At 5 years, success on VAS pain scores, defi ned as a clinically signifi cant change of 20 mm or more compared with preoperative score, was not different between groups for either neck pain ( P = 0.502) or worst arm pain ( P = 0.070) ( Table 1 ) .
Short Form-36 Health Survey
At all postoperative time points for both the mean SF-36 physical component summary and mental component summary scores, both treatment groups improved signifi cantly over preoperative scores ( P < 0.001) ( Figure 5A ,B ). At 5 years, 73.7% of the PCM group reported clinically significant improvement of 15% or more in physical component summary scores compared with 56.7% of the ACDF group ( P = 0.004), whereas 46.2% of the PCM group reported clinically signifi cant improvement in mental component summary scores compared with 54.3% of the ACDF group ( P = 0.189) ( Table 1 ) .
Neurological Success
At 5 years, the neurological success rate was 92.4% (146/158) in the PCM group compared with 87.5% (112/128) in the ACDF group ( P = 0.229) ( Table 1 ) .
Dysphagia
Mean VAS scores for swallowing diffi culty at 5 years were 8.8/100 mm in the PCM group and 16.9/100 mm in the ACDF group ( P = 0.001) ( Table 1 ).
Patient Satisfaction
At 5 years, the mean patient satisfaction VAS scores were 86.9/100 mm and 78.3/100 mm for the PCM and ACDF groups, respectively ( P = 0.005) ( Table 1 ) . When asked whether they were satisfi ed with their 5-year outcomes, 88.8% of the PCM patients responded either "very" or "moderately" satisfi ed, compared with 78.7% of those in the ACDF group. Similarly, 94.4% and 85.0% would "definitely" or "probably" recommend the treatment in the PCM and ACDF groups, respectively.
Serious Adverse Events
Serious adverse events within the fi rst 2 years postoperative were previously reported 5 and showed no statistical difference in incidence between the PCM and ACDF groups. New serious adverse events between 2 years postoperative and current follow-up (up to 7 yr) occurred in 45/214 (21.0%) astreated PCM patients and 33/190 (17.4%) as-treated ACDF patients (denominators include crossover between treatment groups). The majority of these events were systemic or medical in nature, with 1 (0.5%) new device-related serious adverse event in the PCM group and 2 (1.1%) in the ACDF group. Table 2 ). The new events occurring between 2 and 7 years included 6 removals of the PCM device for pain and/or device migration, 3 of those after a trauma, and 1 ACDF for adjacent segment disease. Four of the PCM removals were converted to single-level ACDF, 1 to a 2-level ACDF, and 1 to another arthroplasty. In the ACDF group, 13 of the 14 late-term secondary surgical procedures were for adjacent-level degeneration and 1 was performed for a pseudarthrosis. Patients were treated with either revision and extension of fusion or cervical arthroplasty. Figure 6 illustrates the Kaplan-Meier curves comparing the time to fi rst occurrence of an SSSI between groups, showing the incidence of SSSI at each time point out to 7 years. The curves are not statistically different ( P = 0.123) but begin separating at about 3 years where, as follow-up continues, there is a greater probability of additional surgery in ACDF patients than in PCM patients. ( P = 0.006) ( Table 1 ). Degeneration at the inferiorly adjacent level was radiographically identifi ed about equally in both groups: 49.2% (58/118) in PCM and 51.7% (46/89) in ACDF ( P = 0.779). Figure 8A -F shows the radiographical chronology of a 50-yearold male who presented with signifi cant neck and arm pain (preoperative VAS scores of 77/100 and 91/100, respectively) because of C6-C7 spondylosis and underwent cervical decompression and arthroplasty using the PCM Cervical Disc. Preoperative ( Figure 8A ), immediate postoperative ( Figure 8B ), and 2-year ( Figure 8C ) lateral neutral radiographs showing good postoperative restoration and maintenance of disc height and alignment. Lateral neutral ( Figure 8D ), fl exion ( Figure 8E ), and extension ( Figure 8F ) radiographs at 4-year follow-up, showing continued maintenance of correction, as well as continued motion, despite mild (grade 1) heterotopic ossifi cation posteriorly. The patient returned to all activities within 6 weeks, and at 6 years after surgery, he reports no pain-related disability and complete satisfaction with his treatment.
Radiographical Findings
Case Example
DISCUSSION
The results of the current study demonstrated excellent longterm clinical outcomes in both the PCM and ACDF groups in the treatment of symptomatic single-level cervical spondylosis. Clinical outcomes with the use of the PCM Cervical Disc were superior to instrumented anterior cervical fusion, with signifi cantly better mean NDI, VAS, and SF-36 scores; higher NDI success rate; lower rate of prolonged dysphagia; and greater patient satisfaction scores at 5 years of follow-up.
Cervical motion in PCM patients was maintained at 5 years. In addition, patients undergoing arthroplasty with the PCM Cervical Disc exhibited statistically lower rates of radiographical adjacent-level degeneration and incurred fewer secondary surgical procedures than ACDF controls out to 7 years, representing the longest reported follow-up in the US cervical arthroplasty IDE trials to date.
Results from several prospective, randomized clinical trials of various cervical total disc replacement device designs have been reported, all fi nding at least equivalent clinical outcome measures, rates of secondary surgical interventions, and overall success compared with ACDF at 2 years of follow-up. [1] [2] [3] [4] [5] In a meta-analysis of 2-year outcomes studies, pooled results from 4 cervical disc replacement IDE trials concluded that cervical arthroplasty was superior to ACDF on rate of neurological success, secondary surgical interventions, and overall success, whereas at least equivalent on NDI success. 19 More recently, 5-year outcome data have started to be reported for cervical arthroplasty. [6] [7] [8] [9] [10] [11] [12] [13] The current study supports the durability of results for the PCM arthroplasty device out to at least 5 years, with support for 7-year survivability.
Across multiple trials, including the current study, clinically and statistically signifi cant improvements in patient-reported outcomes are shown after both fusion and cervical arthroplasty procedures, suggesting that both are clinically effective treatment options for symptomatic cervical spondylosis. Interestingly, however, some clinical measures seem to be superior after cervical arthroplasty. Notably, higher mean NDI scores and greater percentage of NDI success rates ( > 15-point or > 20% improvement from baseline) are consistently reported for arthroplasty over fusion across all US IDE trials, 1-13 , 19 although not always statistically different. Although patient euphoric bias (having received a motion-preserving option in a randomized trial vs . fusion) has been suggested to be a factor in 2-year results, it is unlikely that it continues to signifi cantly affect results 5 or more years after the randomization process as was observed in the current trial. 20 In the current study, the differences between groups also increased over time, making euphoric bias less likely, and perhaps explained by survivorship analysis, which showed that fusion patients more often presented with late-term onset of new symptoms, requiring secondary surgery at the adjacent level. These fi ndings suggest that cervical arthroplasty may have a protective effect against accelerated adjacent-level degeneration, which may translate to patient-reported assessment of pain-related function.
Neck pain likely follows a similar pattern with benefi t of arthroplasty over fusion. Again, these results are consistent across arthroplasty trials, in which improvement in neck pain and maintenance of that improvement are better after arthroplasty, even while improvement in arm pain is similar between groups. These results suggest that both procedures provide effective neural decompression, but motion preservation may provide better relief of neck pain, possibly associated with the more physiologic regional kinematics 21 or decreased adjacent segment degeneration.
Another interesting fi nding in the current study was a higher rate of dysphagia in the fusion group even at 5 years postoperative. Prior studies have similarly reported lower rates of dysphagia after cervical arthroplasty than those after ACDF. 7 , 13 Suggested mechanisms include the absence of any anterior profi le of the PCM device that sits entirely intradiscal compared with an anterior cervical plate. Others have suggested that applying an anterior plate requires greater esophageal retraction. 22 In the current trial, both disc height and range of motion at the index level were maintained up to 5 years after PCM. Although heterotopic ossifi cation has been raised as a concern for the long-term mobility of cervical disc replacements, only 6% of PCM patients were classifi ed as grade IV or ankylosed at 5 years postoperative, or alternatively, 94% of PCM patients maintained at least 2 ° of fl exion-extension motion, with an average of 5.2 ° . Loss of disc height was seen early in the postoperative follow-up period in the ACDF group, continuing to decrease through 12 months but then without signifi cant decrease at later time points where it is presumed that the levels fused in the subsided position. Loss of lordosis due to subsidence can cause axial pain and stresses at adjacent levels. 23 Indeed, a higher incidence of radiographical degeneration of the superiorly adjacent segment was observed after ACDF than that after PCM. This trend was seen at 2 years and continued to a signifi cant degree out to 5 years. It should be noted, however, that not all radiographically identifi ed degeneration is necessarily symptomatic or requiring surgical intervention. In the current study, the incidence of secondary surgery was lower for PCM patients than that for ACDF patients, even out to 7 years, as the survivability curves of each treatment diverge in favor of arthroplasty starting at about 3 years postoperative and continue to separate as an increasingly greater number of ACDF patients require additional surgical procedures, mainly for adjacent-level symptoms. These results are similar to those reported in other long-term reports 
